[¹⁷⁷Lu]Lu-PSMA-617 (Pluvicto^TM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer

• Main Authors: Ute Hennrich (Author), Matthias Eder (Author)
• Format: Book
• Published: MDPI AG, 2022-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

In March 2022, [¹⁷⁷Lu]Lu-PSMA-617 (Pluvicto^TM) was approved by the FDA for the treatment of prostate cancer patients. Until now, the approval has been limited to patients with PSMA-positive metastatic castration-resistant prostate cancer who have previou...